Very interesting discovery Titus!
Yes, sells Inhibitex to BMS for US$2.5billion, largely on the back of INX-189 HepC antiviral which BMS subsequently rename BMS-986094 and which is held responsible for a patient fatality, resulting in the discontinuation of the drug's development.
Reads like a scene from a movie.
Is this guy really JR Ewing in disguise??
Possibly a little more research required here.